CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy ...

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes that its portfolio company Imara, Inc. ("Imara") has ...